Correspondence discusses causal interpretation issues in long-term efficacy claims for atopic dermatitis treatments, suggesting caution.
Our correspondence discusses an important interpretive consideration regarding the distinction between persistent response among selected responders and durable disease control in the broader treated population in a recent study of long-term lebrikizumab efficacy in atopic dermatitis. We highlight how responder-enriched analyses, attrition, and treatment persistence may influence interpretation of long-term stability outcomes and encourage cautious interpretation of durability claims in chronic inflammatory skin disease.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: